Janssen AD26 vaccine (JNJ-78436735) (n=21895) vs. placebo (n=21888)
randomized controlled trial
Janssen Ad26.COV2.S vaccine single dose (5x1010 vp) intramuscular
placebo
COVID-19 prophylaxis (excluding children)
double blind
Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, and the United States
ChAdOx1 phase 3 (AstraZeneca), 2020 NCT04400838
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) (n=5807) vs. control (n=5829)
randomized controlled trial
ChAdOx1 nCoV-19 vaccine
ChAdOx1nCoV-19 group received two doses containing 5 × 10¹⁰ viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort)
meningococcal group A, C, W, and Y conjugate vaccine or saline
interval between dose 1 and dose 2 ranged from 4 to 26 weeks
COVID-19 prophylaxis (excluding children)
exclusion criteria: h history of anaphylaxis or angioedema; participants with severe and/or uncontrolled cardiovascular, gastrointestinal, liver, renal, endocrine/metabolic disease, and neurological illnesses; as well as those with immunosuppression
double blind
UK, Brazil, and South Africa.
pooled analysis of 4 studies done across the UK, Brazil, and South Africa : ISRCTN89951424(COV003), NCT04400838 (COV002), NCT04324606 (COV001), and NCT04444674 (COV005).
